Try our Advanced Search for more refined results

OTSUKA PHARMACEUTICAL CO., LTD., et al v. BURWELL et al

  1. July 29, 2016

    Otsuka's 'Convoluted' Logic Spurned In Abilify Maintena Row

    A D.C. federal judge on Thursday rejected Otsuka Pharmaceutical's effort to derail a rival version of schizophrenia drug Abilify Maintena, calling its logic "convoluted" and obviously aimed at perpetually thwarting competition.

  2. January 07, 2016

    Judge Cold To Otsuka's Exclusivity Claims In FDA Row

    A D.C. federal judge on Thursday was harshly skeptical of Otsuka's bid to reverse the U.S. Food and Drug Administration's approval of a rival version of its schizophrenia drug Abilify Maintena, openly doubting that Otsuka's exclusivity was as broad as it claimed.

  3. October 20, 2015

    Otsuka Sues FDA Over Approval Of Abilify Maintena Rival

    Otsuka Pharmaceutical Co. Ltd. is suing in D.C. federal court over the U.S. Food and Drug Administration's approval of a rival version of its schizophrenia drug Abilify Maintena, alleging that "regulatory sleight of hand" improperly nullified its exclusivity.